Today: 30 April 2026
Browse Category

NYSE:NVO 17 January 2026 - 6 February 2026

Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

Hims & Hers Health shares fell 3.8% to $23.48 in premarket trading Friday after FDA Commissioner Marty Makary warned of a crackdown on “illegal copycat drugs.” The drop followed Hims’ launch of a $49 compounded version of Novo Nordisk’s Wegovy pill. Novo Nordisk said it would pursue legal and regulatory action, calling Hims’ move “illegal mass compounding.” Investors are watching for FDA enforcement and lawsuits ahead of Hims’ Feb. 23 report.
6 February 2026
····
Novo Nordisk stock plunges as 2026 sales warning fuels price-war fears around Wegovy

Novo Nordisk stock plunges as 2026 sales warning fuels price-war fears around Wegovy

Novo Nordisk shares fell 16% in Copenhagen after the company warned 2026 sales and profit may drop up to 13% due to falling U.S. drug prices and tougher competition. ADRs slid nearly 4% in New York. Novo plans a share buyback of up to 15 billion Danish crowns and named Jamey Millar as its new U.S. head. CEO Mike Doustdar said Wegovy price cuts have hit results but are meant to boost future demand.
4 February 2026
···
Novo Nordisk stock hammered as Ozempic maker warns 2026 sales may fall up to 13%

Novo Nordisk stock hammered as Ozempic maker warns 2026 sales may fall up to 13%

Novo Nordisk warned adjusted sales and operating profit may fall 5% to 13% in 2026, citing U.S. price cuts and rising competition from Eli Lilly. Shares plunged 18% in early Copenhagen trading. CEO Mike Doustdar called the U.S. price reductions for Wegovy “painful.” Novo also flagged patent expiries and pressure from compounded GLP-1 drugs.
4 February 2026
···
Eli Lilly stock price drops 4% as Novo outlook jars weight-loss trade ahead of earnings

Eli Lilly stock price drops 4% as Novo outlook jars weight-loss trade ahead of earnings

Eli Lilly shares fell 3.9% to $1,003.46 on Tuesday, tracking a sharp 14% drop in Novo Nordisk after its 2026 forecast signaled deeper pricing pressure in the obesity-drug market. Pfizer also slipped on new weight-loss drug data. Lilly will report quarterly results Wednesday, as investors watch for signs of further price cuts and shifting demand in the sector.
4 February 2026
····
Eli Lilly stock slips as obesity-drug price cuts and rival data set up Feb. 4 earnings

Eli Lilly stock slips as obesity-drug price cuts and rival data set up Feb. 4 earnings

Eli Lilly shares fell 1.4% to $1,029.99 by midday Tuesday as U.S. prices for GLP-1 obesity drugs dropped sharply, prompting analysts to cut long-term forecasts. Novo Nordisk and Pfizer reported strong weight-loss data for rival drugs this week, intensifying competition. Investors await Lilly’s earnings update Wednesday for signals on pricing, demand, and supply outlooks.
3 February 2026
·····
Eli Lilly stock price climbs as obesity-drug forecasts get a reality check before earnings

Eli Lilly stock price climbs as obesity-drug forecasts get a reality check before earnings

Eli Lilly shares rose 1.5% to close near $1,052.70 Monday, recovering from early losses ahead of its earnings report due Wednesday. Analysts have cut long-term forecasts for obesity drugs as prices fall and competition intensifies, with 2030 sales estimates for GLP-1 drugs dropping to about $100 billion. Investors are focused on Lilly’s pricing strategy and demand outlook. The FDA is set to rule on Lilly’s weight-loss pill by April 10.
2 February 2026
····
Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Eli Lilly shares rose 1.3% after announcing a $3.5 billion Pennsylvania plant for obesity drugs, helping the Health Care Select Sector SPDR Fund gain 0.6% as the S&P 500 fell. Biotech lagged, with Corcept Therapeutics dropping 10.6% after an FDA rejection. Thermo Fisher slid 2.3% on weak profit guidance. Stryker jumped 4.3% after raising its outlook.
31 January 2026
······
Healthcare stocks brace for a key week: XLV slips as Wegovy pill data and UnitedHealth earnings loom

Healthcare stocks brace for a key week: XLV slips as Wegovy pill data and UnitedHealth earnings loom

The Health Care Select Sector SPDR Fund (XLV) fell 0.5% to $157.48 Friday, with Eli Lilly down 2.1%. Johnson & Johnson and UnitedHealth posted small gains. Traders are watching obesity-drug demand and a crowded earnings calendar next week. The FDA linked ByHeart’s recalled infant formula to a multi-state botulism outbreak.
25 January 2026
·····
Eli Lilly stock slips as obesity-drug headlines pile up ahead of next week

Eli Lilly stock slips as obesity-drug headlines pile up ahead of next week

Eli Lilly shares fell 2.1% to $1,064.29 Friday after analysts reported Novo Nordisk’s new Wegovy pill logged 18,410 U.S. prescriptions in its first full week. Lilly’s Q4 results are due Feb. 4. India approved local firms to make generic semaglutide ahead of its 2026 patent expiry. New data showed many patients did not quickly regain weight after stopping GLP-1 drugs.
24 January 2026
···
Eli Lilly stock slips as Novo’s Wegovy pill racks up 18,000+ scripts; earnings next

Eli Lilly stock slips as Novo’s Wegovy pill racks up 18,000+ scripts; earnings next

Eli Lilly shares fell 1.1% to $1,075.78 after Novo Nordisk’s new Wegovy pill logged over 18,000 U.S. prescriptions in its first full week. Investors are watching ahead of Lilly’s Feb. 4 earnings and an expected FDA decision on its own oral obesity drug by April. Several Lilly directors recently received stock units through a deferral plan.
23 January 2026
····
Novo Nordisk stock price jumps before the bell as Wegovy pill prescriptions leap

Novo Nordisk stock price jumps before the bell as Wegovy pill prescriptions leap

Novo Nordisk shares rose 4.9% to $62.23 in premarket trading after new data showed U.S. prescriptions for the oral Wegovy pill jumped to 20,392 from 4,286. The surge comes as investors watch prescription trends ahead of Novo’s Feb. 4 results. Rival Eli Lilly shares edged up 0.8%. India’s Sun Pharmaceutical won approval to produce generic semaglutide after the patent expires in March.
23 January 2026
·
Novo Nordisk stock jumps on Wegovy pill prescriptions — what investors watch next week

Novo Nordisk stock jumps on Wegovy pill prescriptions — what investors watch next week

Novo Nordisk shares surged 6.49% to 388.90 Danish crowns Friday after early U.S. prescription data for its new Wegovy pill and UK approval of a higher Wegovy dose. U.S. retail pharmacies filled 3,071 Wegovy pill prescriptions in the first four days, not counting online sales. Novo’s ADRs rose 0.74% in New York. Investors await the company’s earnings report on Feb. 4.
18 January 2026
·
1 2 3 4 … 7

Stock Market Today

  • ASX Fast Food Shares Plunge as Rising Living Costs Hit Consumer Spending
    April 30, 2026, 11:22 AM EDT. Shares in major Australian fast food companies including Domino's Pizza, Collins Foods (KFC operator), and Retail Food Group plunged over 10% amid soaring living costs, notably rising fuel prices linked to geopolitical tensions. Consumer confidence in Australia has hit lows not seen since the early pandemic, pressured by inflation hitting 4.6% and increased mortgage costs. Market strategist Lochlan Halloway says fast food, seen as discretionary spending, faces demand cuts alongside rising operational expenses, squeezing earnings outlooks. The downturn underscores growing investor worries that consumers are scaling back on takeaway, despite a steady broader ASX performance.

Latest article

Why FatPipe Stock Jumped Today After Its Government-Contract Push

Why FatPipe Stock Jumped Today After Its Government-Contract Push

30 April 2026
FatPipe shares jumped 18% to $2.92 Thursday after the company announced expanded access to its SD-WAN and cybersecurity products through public-sector procurement channels. The move follows a VeloCloud replacement program targeting customers of Arista Networks’ SD-WAN business. Trading volume reached 42.2 million shares. Investors remain cautious over execution and customer concentration risks.
Why Huachen AI Parking (HCAI) Stock Is Surging: Tiny Float, Reverse Split and Nasdaq Risk

Why Huachen AI Parking (HCAI) Stock Is Surging: Tiny Float, Reverse Split and Nasdaq Risk

30 April 2026
Huachen AI Parking shares surged as much as 135% in heavy Nasdaq trading Thursday, triggering four volatility halts. No new company filings or press releases explained the spike. The rally follows a 1-for-30 reverse stock split effective April 13, which sharply reduced the share count. Trading volume reached 34 million shares, far above the average of 727,390.
Altria Stock Jumps 7% After Marlboro Maker Beats Q1 Forecasts on Price Hikes

Altria Stock Jumps 7% After Marlboro Maker Beats Q1 Forecasts on Price Hikes

30 April 2026
Altria posted adjusted earnings of $1.32 per share and net revenues of $5.43 billion for the quarter, beating analyst estimates. Higher prices offset falling cigarette volumes, with domestic shipments down 2.4%. Shares rose about 7% in late-morning trading. CEO Billy Gifford is set to step down in mid-May.
Go toTop